Table 1 Characteristics of study patients
Characteristics | Overall | Tertiles of stent diameter of 2522 patients | |||
|---|---|---|---|---|---|
T1 (≤ 2.85) | T2 (2.86–3.20) | T3 (≥ 3.21) | P value | ||
N | 2522 | 837 | 826 | 859 | |
TVR | 122 (4.8%) | 58 (6.9%) | 32 (3.9%) | 32 (3.7%) | 0.003 |
Demographics | |||||
Age (years) | 60.0 ± 11.1 | 61.3 ± 10.6 | 60.5 ± 10.8 | 58.2 ± 11.6 | < 0.001 |
Male, n (%) | 1715 (68.0%) | 518 (61.9%) | 566 (68.5%) | 631 (73.5%) | < 0.001 |
Medical history | |||||
Hypertension, n (%) | 1240 (49.2%) | 447 (53.4%) | 415 (50.2%) | 378 (44.1%) | < 0.001 |
Diabetes mellitus, n (%) | 520 (20.6%) | 217 (25.9%) | 170 (20.6%) | 133 (15.5%) | < 0.001 |
Atrial fibrillation, n (%) | 50 (2.0%) | 12 (1.4%) | 17 (2.1%) | 21 (2.4%) | 0.322 |
Stroke, n (%) | 133 (5.3%) | 45 (5.4%) | 54 (6.5%) | 34 (4.0%) | 0.06 |
III degree AVB, n (%) | 8 (0.3%) | 4 (0.5%) | 1 (0.1%) | 3 (0.3%) | 0.506 |
COPD, n (%) | 22 (0.9%) | 3 (0.4%) | 11 (1.3%) | 8 (0.9%) | 0.100 |
Heart failure, n (%) | 294 (11.7%) | 109 (13.0%) | 98 (11.9%) | 87 (10.1%) | 0.173 |
Cardiac shock, n (%) | 4 (0.2%) | 0 (0.0%) | 1 (0.1%) | 3 (0.3%) | 0.281 |
PVD, n (%) | 6 (0.2%) | 3 (0.4%) | 2 (0.2%) | 1 (0.1%) | 0.542 |
MI, n (%) | 233 (9.2%) | 84 (10.0%) | 89 (10.8%) | 60 (7.0%) | 0.017 |
Smoking, n (%) | 811 (32.2%) | 243 (29.0%) | 259 (31.4%) | 309 (36.0%) | 0.008 |
Prior CABG, n (%) | 21 (0.8%) | 8 (1.0%) | 6 (0.7%) | 7 (0.8%) | 0.874 |
Prior PCI, n (%) | 169 (6.7%) | 59 (7.0%) | 58 (7.0%) | 52 (6.1%) | 0.65 |
Medication | |||||
Aspirin, n (%) | 2487 (98.7%) | 823 (98.3%) | 814 (98.7%) | 850 (99.1%) | 0.406 |
Clopidogrel, n (%) | 2415 (95.9%) | 803 (96.2%) | 792 (95.9%) | 820 (95.6%) | 0.429 |
β-blocker, n (%) | 1711 (67.8%) | 552 (65.9%) | 575 (69.6%) | 584 (68.0%) | 0.277 |
ACEI, n (%) | 1350 (53.6%) | 433 (51.7%) | 453 (54.9%) | 464 (54.0%) | 0.407 |
CCB, n (%) | 598 (23.7%) | 211 (25.2%) | 192 (23.2%) | 195 (22.7%) | 0.444 |
Statin, n (%) | 2293 (90.9%) | 750 (89.6%) | 762 (92.3%) | 781 (90.9%) | 0.172 |
Laboratory tests | |||||
LDL-C, mmol/L | 2.7 ± 0.9 | 2.7 ± 0.9 | 2.7 ± 0.9 | 2.7 ± 0.9 | 0.638 |
HDL-C, mmol/L | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.1 ± 0.3 | 0.549 |
TC, mmol/L | 4.3 ± 1.1 | 4.3 ± 1.0 | 4.2 ± 1.1 | 4.3 ± 1.1 | 0.563 |
Creatinine, mmol/L | 69.0(58.0–81.0) | 67.0(56.0–80.0) | 70.0(58.0-81.8) | 70.0(59.0–82.0) | 0.034 |
Glycemia, mmol/L | 5.2 (4.7–6.3) | 5.4 (4.7-7.0) | 5.2 (4.6–6.2) | 5.1 (4.6–6.1) | < 0.001 |
Stent information | |||||
Length of stent, mm | 50.1 ± 32.6 | 53.7 ± 32.5 | 57.2 ± 35.4 | 39.8 ± 27.0 | < 0.001 |
Left main stem, n (%) | 86 (3.4%) | 13 (1.6%) | 22 (2.7%) | 51 (5.9%) | < 0.001 |
LAD, n (%) | 2084 (82.6%) | 697 (83.3%) | 717 (86.8%) | 670 (78.0%) | < 0.001 |
LCX, n (%) | 1217 (48.3%) | 501 (59.9%) | 452 (54.7%) | 264 (30.7%) | < 0.001 |
RCA, n (%) | 1249 (49.5%) | 399 (47.7%) | 444 (53.8%) | 406 (47.3%) | 0.012 |
Bifurcation lesion, n (%) | 443 (17.6%) | 159 (19.0%) | 142 (17.2%) | 142 (16.5%) | 0.387 |
Ostial lesions, n (%) | 274 (10.9%) | 76 (9.1%) | 92 (11.1%) | 106 (12.3%) | 0.093 |
CTO, n (%) | 224 (8.9%) | 94 (11.2%) | 68 (8.2%) | 62 (7.2%) | 0.011 |
Stent type | < 0.001 | ||||
SES, n (%) | 1643 (65.2%) | 491 (58.7%) | 582 (70.5%) | 570 (66.4%) | |
PES, n (%) | 502 (19.9%) | 184 (22.0%) | 122 (14.8%) | 196 (22.8%) | |
BMS, n (%) | 377 (14.9%) | 162 (19.4%) | 122 (14.8%) | 92 (10.8%) | |
Clinical presentation | 0.317 | ||||
Urgent PCI, n (%) | 99 (3.9%) | 31 (3.7%) | 30 (3.6%) | 38 (4.4%) | |
Delayed PCI, n (%) | 519 (20.6%) | 169 (20.2%) | 179 (21.7%) | 171 (19.9%) | |
NSTE-ACS, n (%) | 1488 (59.0%) | 493 (58.9%) | 468 (56.7%) | 527 (61.4%) | |
SA, n (%) | 416 (16.5%) | 144 (17.2%) | 149 (18.0%) | 123 (14.3%) | |